Viridian Therapeutics Prepares for Transformational 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
TD Cowen on Viridian Therapeutic (VRDN): 'VRDN is a Top Pick'
January 6, 2026 3:14 PM ESTTD Cowen analyst Joseph Thome reiterated a Buy rating on Viridian Therapeutic (NASDAQ: VRDN).
The analyst comments "VRDN provided a roadmap for a busy 2026. A BLA for veligrotug in TED is under priority review with a June 30, 2026 PDUFA date set.... More
